Desonide foam 0.05%: Safety in children as young as 3 months

Journal of the American Academy of Dermatology

Volumn 59, Issue 2, 2008, Pages 334-340

  Hebert, Adelaide A ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESONIDE;

ADOLESCENT; ADRENAL SUPPRESSION; APPLICATION SITE ATROPHY; APPLICATION SITE BURNING; APPLICATION SITE DERMATITIS; APPLICATION SITE DESQUAMATION; APPLICATION SITE DRYNESS; APPLICATION SITE ERYTHEMA; APPLICATION SITE INFECTION; APPLICATION SITE PIGMENTATION CHANGE; APPLICATION SITE PRURITUS; APPLICATION SITE REACTION; APPLICATION SITE URTICARIA; ARTICLE; ATOPIC DERMATITIS; CELLULITIS; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EAR INFECTION; FEMALE; FEVER; GROUPS BY AGE; HEADACHE; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM SUPPRESSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ANTI-INFLAMMATORY AGENTS; CHILD; CHILD, PRESCHOOL; DERMATITIS, ATOPIC; DESONIDE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; INFANT; MALE; PITUITARY-ADRENAL SYSTEM; TREATMENT OUTCOME; UNITED STATES;

EID: 47049092199     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2008.04.019     Document Type: Article

References (15)

1. Kiken D.A., and Silverberg N.B. Atopic dermatitis in children, part 1: epidemiology, clinical features, and complications. Cutis 78 (2006) 241-247
2. Hanifin J.M., and Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 92 (1980) 44-47
3. Williams H.C. Clinical practice: atopic dermatitis. N Engl J Med 352 (2005) 2314-2324
4. Simpson E.L., and Hanifin J.M. Atopic dermatitis. Med Clin North Am 90 (2006) 149-167
5. Ellis C., Luger T., Abeck D., Allen R., Graham-Brown R.A., De Prost Y., et al. ICCAD II Faculty. International consensus conference on atopic dermatitis II (ICCAD II): clinical update and current treatment strategies. Br J Dermatol 148 Suppl (2003) 3-10
6. Tofte S.J., and Hanifin J.M. Current management and therapy of atopic dermatitis. J Am Acad Dermatol 44 Suppl (2001) S13-S16
7. Hanifin J.M., Cooper K.D., Ho V.C., Kang S., Krafchik B.R., Margolis D.J., et al. Guidelines of care for atopic dermatitis. J Am Acad Dermatol 50 (2004) 391-404
8. Levin C., and Maibach H.I. Topical corticosteroid-induced adrenocortical insufficiency: clinical implications. Am J Clin Dermatol 3 (2002) 141-147
9. Lucky A.W., Grote G.D., Williams J.L., Tuley M.R., Czernielewski J.M., Dolak T.M., et al. Effect of desonide ointment, 0.05%, on the hypothalamic-pituitary-adrenal axis of children with atopic dermatitis. Cutis 59 (1997) 151-153
10. Munro D.D. The effect of percutaneously absorbed steroids on hypothalamic-pituitary-adrenal function after intensive use in in-patients. Br J Dermatol 94 Suppl (1976) 67-76
11. Prawer S.E., Katz H.I., Herndon Jr. J.H., Baker M.D., and Cheney T. Controlled, bilateral, comparative evaluation of 0.05% desonide lotion and desonide cream in eczematous dermatitis. Curr Ther Res 53 (1993) 607-613
12. Bluefarb S.M. Clinical comparison of desonide cream with betamethasone valerate cream: a double-blind randomized study. Int J Dermatol 11 (1972) 73-76
13. Gentry Jr. W.C., Rosenberg E.W., and Goltz R.W. A clinical evaluation of 0.05% desonide cream: a new nonfluorinated topical corticosteroid. Arch Dermatol 107 (1973) 870-871
14. Jorizzo J., Levy M., Lucky A., Shavin J., Goldberg G., Dunlap F., et al. Multicenter trial for long-term safety and efficacy comparison of 0.05% desonide and 1% hydrocortisone ointments in the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 33 (1995) 74-77
15. Hebert A.A., Cook-Bolden F.E., Basu S., Calvarese B., and Trancik R.J. Desonide Hydrogel Study Group. Safety and efficacy of desonide hydrogel 0.05% in pediatric subjects with atopic dermatitis. J Drugs Dermatol 6 (2007) 175-181